RECENT ADVANCES IN CANCER DIAGNOSIS: INTEGRATION OF LIQUID BIOPSY, MOLECULAR BIOMARKERS, ARTIFICIAL INTELLIGENCE, AND ADVANCED IMAGING

Dr **Khadka Ravi Roshan**, MBBS, MS
Associate Professor
dr.ravi7209@gmail.com
Faculty of International Students, Asia International University

Abstract

Early and accurate diagnosis of cancer is crucial for improving patient outcomes and survival rates. In recent years, rapid technological progress has transformed the field of cancer diagnostics, enabling earlier detection and more precise characterization of tumors. Novel diagnostic approaches such as liquid biopsy, molecular biomarkers, artificial intelligence (AI), and advanced imaging techniques are increasingly being integrated into clinical practice. Liquid biopsy allows non-invasive detection of tumor-derived components such as circulating tumor DNA and circulating tumor cells. Molecular biomarkers provide valuable insights into genetic and epigenetic alterations associated with malignancy. Artificial intelligence has demonstrated significant potential in enhancing radiological and histopathological interpretation, improving diagnostic accuracy and efficiency. Additionally, advanced imaging modalities including functional MRI and PET-CT offer improved tumor visualization and staging. The integration of these innovative technologies represents a paradigm shift toward precision oncology, enabling earlier detection, personalized treatment planning, and better monitoring of disease progression. This review summarizes recent advances in cancer diagnosis and highlights the potential of integrating emerging diagnostic technologies to improve cancer detection and management.

Keywords

cancer diagnosis, liquid biopsy, molecular biomarkers, artificial intelligence, advanced imaging, precision oncology

Introduction

Cancer remains one of the leading causes of morbidity and mortality worldwide. Early detection plays a vital role in improving survival rates, reducing treatment costs, and enhancing quality of life for patients. Traditional diagnostic approaches such as tissue biopsy, histopathology, and conventional imaging techniques have long been considered the gold standard for cancer diagnosis. However, these methods have certain limitations, including invasiveness, sampling bias, and challenges in detecting early-stage disease (1).

Recent advances in biomedical research and digital technologies have led to the development of innovative diagnostic tools that can detect cancer earlier and more accurately. Technologies such as liquid biopsy, molecular biomarker analysis, artificial intelligence-assisted diagnostics, and advanced imaging techniques have significantly improved the ability to identify tumors at an early stage and characterize their molecular profiles (2).

This review aims to discuss recent advances in cancer diagnosis, focusing on the integration of emerging technologies that are transforming modern oncology practice.

Liquid Biopsy in Cancer Diagnosis

1531

Liquid biopsy has emerged as a promising non-invasive diagnostic tool for detecting and monitoring cancer. Unlike conventional tissue biopsy, liquid biopsy involves analyzing tumor-derived components present in body fluids such as blood, urine, or saliva (3).

Key components analyzed in liquid biopsy include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles such as exosomes. These biomarkers provide valuable information about tumor genetics, mutation status, and disease progression (4).Liquid biopsy offers several advantages over traditional biopsy methods. It is minimally invasive, allows repeated sampling, and can capture tumor heterogeneity more effectively. Additionally, it has shown potential for early cancer detection, monitoring treatment response, and identifying minimal residual disease after therapy (5).Despite its promising potential, challenges remain in terms of sensitivity, standardization, and clinical implementation. Nevertheless, ongoing research continues to improve the accuracy and reliability of liquid biopsy technologies.


Fig 1; Liquid biopsy in cancer diagnosis

Molecular Biomarkers and Genomic Profiling

Molecular biomarkers have become essential tools in modern cancer diagnostics. These biomarkers include genetic mutations, epigenetic alterations, proteins, and metabolites associated with tumor development and progression (6).

Advances in genomic technologies such as next-generation sequencing (NGS) have enabled comprehensive analysis of cancer-related genetic alterations. NGS allows simultaneous detection of multiple mutations across numerous genes, providing detailed molecular insights into tumor biology (7).Molecular biomarker analysis has improved early cancer detection and enabled more precise tumor classification. Furthermore, biomarker-based diagnostics play a key role in precision oncology by guiding targeted therapy and personalized treatment strategies.Examples of clinically relevant biomarkers include HER2 in breast cancer, EGFR mutations in lung cancer, and KRAS mutations in colorectal cancer. These biomarkers not only assist in diagnosis but also influence therapeutic decision-making.

Fig 2; Molecular diagnostic in breast cancer

Artificial Intelligence in Cancer Diagnosis

Artificial intelligence has rapidly gained importance in medical diagnostics, particularly in oncology. AI algorithms, especially deep learning models, can analyze large datasets from imaging, pathology slides, and genomic profiles to detect patterns that may not be easily recognized by human observers (8).

In radiology, AI-assisted image analysis can improve detection of tumors in mammography, computed tomography (CT), and magnetic resonance imaging (MRI). Studies have shown that AI-based systems can achieve diagnostic accuracy comparable to or even exceeding that of experienced radiologists in certain scenarios (9).AI is also transforming digital pathology by enabling automated analysis of histopathological slides. Machine learning models can assist in tumor grading, classification, and identification of subtle morphological features associated with malignancy. The integration of AI into clinical practice has the potential to enhance diagnostic efficiency, reduce human error, and support clinical decision-making.

1533

Advanced Imaging Techniques in Cancer Detection

Imaging plays a crucial role in cancer diagnosis, staging, and treatment planning. Advances in imaging technology have significantly improved the detection and characterization of tumors. Positron emission tomography combined with computed tomography (PET-CT) provides both functional and anatomical information, enabling precise localization of malignant lesions (10). Functional imaging techniques such as diffusion-weighted MRI and dynamic contrast-enhanced MRI offer improved sensitivity for detecting early tumors and assessing tumor aggressiveness.


*Fig 3;   Dynamic contrast-enhanced MRI   Fig 4; PET/*

Radiomics is another emerging field that involves extracting quantitative features from medical images to predict tumor behavior and treatment response (11). By combining imaging data with artificial intelligence algorithms, radiomics has the potential to enhance diagnostic accuracy and facilitate personalized cancer management.

Integration of Emerging Technologies in Precision Oncology

The future of cancer diagnosis lies in the integration of multiple diagnostic technologies. Combining liquid biopsy, molecular biomarker analysis, artificial intelligence, and advanced imaging can provide a more comprehensive understanding of tumor biology.For example, integrating genomic data with imaging findings can improve tumor characterization and guide targeted therapy. Similarly, AI algorithms can analyze data from liquid biopsy and imaging simultaneously to detect early cancer signals and predict disease progression (12).This multidisciplinary approach aligns with the principles of precision oncology, where diagnosis and treatment are tailored according to the individual patient's molecular and clinical profile.

Conclusion

Recent advances in cancer diagnostics have significantly improved the ability to detect and characterize tumors at earlier stages. Technologies such as liquid biopsy, molecular biomarker

analysis, artificial intelligence, and advanced imaging are transforming the landscape of cancer diagnosis. The integration of these innovative approaches offers significant potential for improving diagnostic accuracy, enabling personalized treatment strategies, and enhancing patient outcomes. Continued research and collaboration between clinicians, researchers, and technology experts will be essential to fully realize the benefits of these emerging diagnostic technologies in clinical practice.

References:

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA Cancer J Clin. 2021;71(3):209-249.

2. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140-146.

3. Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, et al. Liquid biopsies come of age. Nat Rev Cancer. 2017;17(4):223-238.

4. Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA. Nat Rev Clin Oncol. 2016;13(6):325-337.

5. Bardelli A, Pantel K. Liquid biopsies and tumor evolution. Cancer Cell. 2017;31(2):172-173.

6. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5(11):845-856.

7. Mardis ER. Next-generation sequencing platforms. Annu Rev Anal Chem. 2013;6:287-303.

8. Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. Dermatologist-level classification of skin cancer with deep neural networks. Nature. 2017;542:115-118.

9. McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. International evaluation of an AI system for breast cancer screening. Nature. 2020;577:89-94.

10. Jadvar H. FDG PET in oncology: basics and clinical applications. J Nucl Med. 2016;57(Suppl 1):144S-150S.

11. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, Timmeren JV, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14(12):749-762.

12. Hood L, Friend SH. Predictive, personalized, preventive, participatory medicine (P4 medicine). Nat Rev Clin Oncol. 2011;8(3):184-187.